BioXcel Therapeutics (BTAI) Interest Expenses (2019 - 2026)

BioXcel Therapeutics' Interest Expenses history runs 8 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 7.44% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $16.3 million (up 7.22% YoY), while the FY2025 annual figure was $17.0 million, up 15.84% from the prior year.
• Interest Expenses was $3.7 million for Q1 2026 at BioXcel Therapeutics, down from $4.4 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $4.4 million in Q4 2025 to a low of $7000.0 in Q1 2022.
• Historically, Interest Expenses has averaged $3.3 million across 5 years, with a median of $3.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Interest Expenses surged 57533.33% in 2022, then declined 17.46% in 2023.
• A 5-year view of Interest Expenses shows it stood at $3.5 million in 2022, then fell by 9.54% to $3.1 million in 2023, then gained by 21.8% to $3.8 million in 2024, then grew by 15.38% to $4.4 million in 2025, then declined by 15.92% to $3.7 million in 2026.
• The last three Interest Expenses figures came in at $3.7 million (Q1 2026), $4.4 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.